SBIR/STTR Research Award

Microarray Detection of MDR-TB

Award identifier 92f37dc757851bfa8b7ea99afeec4baec12521d5a5f161b661c9258d9ef2dab5Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$584,402

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Life Biomed, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Multi-drug resistant TB (MDR-TB) poses a significant threat to treatment and is a Category C bioterror agent. The current identification of MDR-TB still relies on culture and takes 2-6 weeks because of the slow growth of M. tuberculosis. Despite recent progress in understanding the molecular basis of drug resistance in M. tuberculosis, a rapid and reliable molecular method to identify drug resistance is still lacking. Molecular identification of mutations in the genes associated with drug resistance offers an opportunity to rapidly detect drug resistant TB and eliminates the need for the time-consuming phenotype-based susceptibility testing. However, the current molecular methods such as PCR-SSCP, heteroduplex formation etc. are tedious and do not demonstrate required sensitivity or high-throughput sample screening capability. Although DNA sequencing is the most accurate and reliable method for mutation detection, it is expensive, ill-suited for high throughput screening of multiple genes involved in resistance or for resistance mutations not clustered in a sizable target gene. In a preliminary study, we have developed a microarray methodology using overlapping short oligoprobes that can reliably and rapidly detect pncA mutations in pyrazinamide-resistant strains. In this project, we would like to extend this work to incorporate the use of microarray in detection of mutations in multiple genes involved in resistance to several other TB drugs. This technique allows for analysis of all important drug resistance genes in a single hybridization. The goal of this Phase I application is to develop a simple and high-throughput microarray test for rapid detection of MDR-TB. The specific aims of this Phase I SBIR application are: (1) To design microarray oligoprobes based on multiple genes involved in M. tuberculosis drug resistance; (2) To fabricate microarray chip; (3) To evaluate the chip using random mutant libraries; (4) To test the feasibility of microarray hybridization profiles for detection of MDR-TB. Such a rapid microarray test will provide timely information for the treatment and containment of MDR-TB.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.